INVA

18.4100.00%
PR

Pavel Raifeld

CEO & Director

Mr. Pavel Raifeld, C.F.A., is Director of Beacon Biosignals, Inc. Mr. Raifeld is Director of Syndeio Biosciences, Inc. He is a Director of La Jolla Pharmaceutical Company since August 22, 2022. He serves as Chief Executive Officer of Innoviva, Inc. since May 2020 and serves as its Director. He is a seasoned healthcare executive with a strong background in strategy, business development and corporate finance and has focused much of his career on the creation of significant shareholder value. He served on the investment team at Sarissa Capital Management LP. He was a senior member of the healthcare investment banking team at Credit Suisse (USA) LLC. Previously, Mr. Raifeld worked as a consultant, primarily specializing in advising biopharmaceutical companies, at McKinsey & Company, Inc. and The Boston Consulting Group Ltd. Mr. Raifeld earned an AB degree from Harvard University and an MBA degree from Columbia University.

Positions